CheapInsurance.com reports that a new $2,000 out-of-pocket cap under Medicare Part D will save millions, but challenges remain in drug pricing and access.

Bristol Myers Squibb (NYSE:BMY) just got a boost in its Alzheimer's program after the FDA granted Fast Track designation to ...

PepGen Inc. has seen its DM1 trials advance to phase 2 with a great reaction from markets. Click here to read my latest ...

Amgen Inc. (NASDAQ:AMGN) has become the latest major drugmaker to bend to President Donald Trump's intensifying campaign to ...

Results from a large trial suggest baxdrostat could provide a new option for people whose blood pressure remains high despite standard treatment.

Editorial: City Council’s effort to curb discount retailers raises difficult questions.Baltimore City Council’s effort to curb discount retailers raises difficult questions.

The news has recently been awash with stories about the link between acetaminophen (paracetamol) and autism. The White House ...

Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo Nordisk's Wegovy and Eli Lilly's Mounjaro ...

The prospect of tariffs on foreign-made pharmaceuticals had spurred fears of higher drug prices and shortages of critical ...

Virginia’s bipartisan Joint Commission to Oversee Transition of the Commonwealth into a Retail Cannabis Market spent Monday ...

Hale downplayed the Palantir connection, describing it as a “small commercial relationship.” A spokesperson told Slate that ...